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Background: The prevalence of insomnia and hypersomnia in depressed individuals
is substantially higher than that found in the general population. Unfortunately,
these concurrent sleep problems can have profound effects on the disease course.
Although the full biology of sleep remains to be elucidated, a recent genome-wide
association (GWAS) of insomnia, and other sleep traits in over 1 million individuals
was recently published and provides many promising hits for genetics of insomnia in
a population-based sample.
Methods: Using data from the largest available GWAS of insomnia and other sleep
traits, we sought to test if sleep variable PRS scores derived from population-based
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studies predicted sleep variables in samples of depressed cases [Psychiatric Genomics
Consortium - Major Depressive Disorder subjects (PGC MDD)]. A leave-one-out analysis
was performed to determine the effects that each individual study had on our results.
Results: The only significant finding was for insomnia, where p-value threshold, p =
0.05 was associated with insomnia in our PGC MDD sample (R2 = 1.75−3, p = 0.006).
Conclusion: Our results reveal that <1% of variance is explained by the variants that
cover the two significant p-value thresholds, which is in line with the fact that depression
and insomnia are both polygenic disorders. To the best of our knowledge, this is the first
study to investigate genetic overlap between the general population and a depression
sample for insomnia, which has important treatment implications, such as leading to
novel drug targets in future research efforts.
Keywords: sleep, major depressive disorder, insomnia, hypersomnia, polygenic risk
INTRODUCTION
Sleep disorders are not an uncommon phenomenon in society.
Insomnia, marked by an inadequate amount of sleep or quality
of sleep, affects about 17% of Canadians (1). The opposite of
insomnia, hypersomnia, is characterized by excessive sleepiness
or daytime sleep, affects about 8% of individuals (2, 3). Sleep
disturbances are known risk factors for diseases such as coronary
heart disease, diabetes and arthritis, and an overall poorer quality
of life (4).
A close relationship also exists between sleep disturbances and
psychiatric disorders (5). More specifically, research suggests that
sleep disturbances can precede the onset of depression (6, 7).
Prevalence rates for insomnia and hypersomnia are much higher
among depressed individuals population; about 44–88% suffer
from insomnia while 25% experience hypersomnia (8). These
concurrent sleep problems lead to poorer patient outcomes,
including a decreased remission rate, and a greater risk of suicide
and suicidal ideation (9–12).
Although the full biology behind sleep remains to be fully
elucidated, we do know sleep is, at least partially, regulated by
genes via circadian rhythms. Circadian rhythms are believed to
be one component of the sleep-wake cycle. They are an internal
timing mechanism that uses external stimuli to entrain/maintain
a 24-h cycle. This leads to external expression of this internal
mechanism. The most prevalent and persistent stimulus for
mammals is the light-dark cycle (13, 14). There is a group
of genes, known as the core circadian or clock genes, which
are part of a series of transcriptional-translational feedback
loops that help regulate the circadian rhythmicity (15). Some
of the core circadian genes have been implicated in both major
depression and accompanying sleep problems, albeit with mixed
findings (16).
A recent, genome-wide association study (GWAS) (17) in
over 1.3 million individuals from two large studies, the UK
Biobank and 23 and Me. In this study, they reported numerous
significant loci for insomnia, dozing and napping (characteristic
of hypersomnia). Here we use a polygenic risk score (PRS)
analysis to determine if hits for these three phenotypes have a
shared genetic architecture with insomnia and hypersomnia in
individuals diagnosed with major depression.
METHODS
Study Cohorts
For these analyses we utilized de-identified sleep phenotype and
GWAS data on self-identified European-ancestry participants in
studies that are part of the Psychiatric Genomics Consortium-
Major Depressive Disorder Working Group (PGC MDD) (18),
with permission of the investigators. There were 20 studies
with appropriate phenotypic data. After excluding studies
that we did not have permission to use, that did not have
cleaned X-chromosome data, and/or had studies with ID
discrepancies between the phenotype and genotype data, we
had 13 samples. After implementing quality control procedures
(described below), we were left with 11 studies, consisting of N
= 6,963 MDD cases. These 11 studies were: 1) the Cognitive
Function and Mood Study (COFAMS), Genetics of Recurrent
Early-Onset Depression Phase II (GENRED2), Netherlands
Twin Register/Netherlands Study of Depression and Anxiety
(NTR/NESDA), Queensland Institute of Medical Research
cohorts (QIMRI610, QIMRI317, and QIMR COEX), RADIANT
(German, Irish and US cases) and Sequenced Treatment
Alternatives to Relieve Depression (STAR∗D). All cases were
determined to have lifetime MDD diagnosis based on direct
interviews or clinician administered DSM-IV checklists (19). All
individuals provided informed consent. Ethical clearance was
completed for each study across all studies and further details can
be found in the individual references for each study (Table 1).
Sleep Phenotype Data
Self-reported sleep data was extracted from two statements
from the PGC-MDD phenotype file that were derived from
responses to questions in various research interviews or
questionnaires about sleep problems during major depressive
episodes (Table 1). The first statement was “Insomnia nearly
every day,” and the second statement was “Hypersomnia nearly
every day.” Outcomes were binary with 1 representing “yes” and 0
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Samples included in study
Insomnia Hypersomnia
Present (%) Total Female:
Male
Present (%) Total Female:
Male
COFAMS COF2 (20) Australia 120 Hamilton anxiety and
depression rating scale
(21)
92 (78.63) 117 72:45 8 (6.90) 116 72:44
GenRED2 GRND (22) United States
of America
830 Diagnostic interview for
genetic studies 3.01
MD (22)
465 (63.09) 737 610:127 416 (56.45) 737 610:127
NESDA+NTR NES1 (23–25) Netherlands 1494 Composite
international diagnostic
interview (26)
987 (71.99) 1,371 929:442 569 (41.50) 1,371 929:442
QIMR I610 QI6C (27) Australia 499 Composite
international diagnostic
interview (26)
414 (85.54) 484 336:148 138 (28.63) 482 335:147
QIMR I317 QI3C (27) Australia 864 Composite
international diagnostic
interview (26)
486 (83.94) 579 327:252 83 (14.36) 578 326:252
QIMR COEX QIO2 (27) Australia 565 Composite
international diagnostic
interview (26)
452 (82.48) 548 390:158 108 (19.82) 545 389:156
RADIANT RAD3 (28) United Kingdom 1,872 Schedules for clinical
assessment in
neuropsychiatry (29)




RAGE (28) Germany 322 Schedules for clinical
assessment in
neuropsychiatry (29)
241 (77.00) 313 208:105 31 (10.20) 304 200:104
RADIANT -
Irish cases
RAI2 (28) Ireland 109 Schedules for clinical
assessment in
neuropsychiatry (29)
14 (66.67) 21 17:4 3 (15.00) 20 15:5
RADIANT -
US cases
RAU2 (28) United States
of America
223 Schedules for clinical
assessment in
neuropsychiatry (29)
18 (62.07) 29 22:7 10 (34.48) 29 19:10
STAR*D STM2 (30) United States
of America
936 The inventory of
depressive
symptomology (31, 32)
899 (99.12) 907 543:364 214 (23.59) 907 543:364
COFAMS, Cognitive Function and Mood Study; GENRED2, Genetics of Recurrent Early-Onset Depression Phase II; NESDA, The Netherlands Study of Depression and Anxiety; NTR,
Netherlands Twin Registry; QIMR, Queensland Institute for Medical Research; STAR*D, Sequenced Treatment Alternatives to Relieve Depression.
representing “no.” Individuals with “NA” for the sleep phenotype
data were excluded from the study.
Genotype Quality Control
We used imputed plink files that were created using the
RICOPILI modules provided by PGC-MDD (33). Genotype
quality control (QC) procedures were done using PLINK v
1.9 and 2.0 software (34) according to standard genome-wide
association procedures.
The following QC procedures were conducted: individuals
with sex incongruences were identified (F > 0.8 = male and
F < 0.2 = female) and removed (as well as individuals with
no self-reported sex data to compare), individual missingness
was capped at 2%, all individuals that were related (using
identity-by-descent, IBD; pi_hat > 0.2) were removed, and
individuals that were +/- 3 standard deviations away from
the mean heterozygosity were removed. To determine genetic
ancestry, we performed multi-dimensional scaling and a
principal components analysis (PCA). We plotted our samples
against the 1000 Genomes Phase 3 reference population (35)
using R (36) to determine individuals of European ancestry.
With our PCA analyses, we removed everyone that was
further than +/- 6 standard deviations away from the mean.
Finally, individuals with no phenotype data and individuals
that overlapped with the UK Biobank data were removed.
After these steps we noticed there were N = 4 individuals
that were missing the sex call in the .fam file, so they
were removed.
After merging SNPs that were present in all the samples,
SNPs were removed if they did not meet the following
parameters: minor allele frequency (MAF; the SNP variant with
the lower frequency) 1% or greater, missingness 2% or less, and
Hardy-Weinberg equilibrium of 0.000001. In total, 2,484,281
markers were left.
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Insomnia and Hypersomnia (PGC-MDD)
Sample Set-Up
We created two datasets based on our phenotype data: (1)
Insomnia, coded as MDD4a in the PGC phenotype file (N =
6,698), where subjects who had NA for MDD4a (insomnia) were
removed and (2) Hypersomnia, coded as MDD4b in the PGC
phenotype file (N = 6,375), where subjects who had NA for
MDD4b (hypersomnia) were removed. Each sample underwent
another round of marker QC; SNPs that were not in HWE of 1×
10−6, had MAF of <1% or had missingness >2% were removed.
PCAwas performed on each sample separately. After plotting the
principal components (PCs), a scree plot revealed that the first
3 PCs should be included in our analyses as covariates. Other
covariates that were included were sex, and a study indicator.
Summary Statistics QC
Publicly available summary statistics from the study from the
Jansen study (17) on over N = 386,000 individuals from the UK
Biobank data were used for PRS calculations. More specifically,
summary statistics for insomnia, napping and dozing were used.
After removing duplicate SNPs, we excludedmarkers with aMAF
<1%. Info scores of all variants included in the summary statistics
were already 0.9 or greater.
Construction of the PRS
Clumping based on linkage disequilibrium performed using the
default PRSice settings. A binary case-control PRS was conducted
using PRSice using the fast-score option (v2) (37). Next, we
extracted the PRS results for each sample across each of the three
phenotypes (insomnia, napping, dozing). A linear regression was
performed for each independent sample with the PRS scores
being the dependent variable (PRS score ∼ Sex + 3 PCs) for
each of the 8 p-value thresholds (p= 0.001, 0.05, 0.1, 0.2, 0.3, 0.4,
0.5, 1). A logistic regression was performed on the sample, using
the self-reported sleep data as the dependent variable and the
standardized residuals as the independent variable. Nagelkerke’s
R2 was used to calculate what amount of the variance was
explained by the PRS. Bar graphs were plotted using script
from the PRSice website (https://choishingwan.github.io/PRS-
Tutorial/plink_visual/). The Bonferroni method was applied for
multiple testing. Finally, for significant results, a leave-one-out
approach was taken to determine if any of the individual studies
were driving the results in our total sample.
RESULTS
The prevalence of insomnia in our sample was 77.8% while
hypersomnia was only present in 29.7%.
N = 4,583 (68%) of individuals were female in the insomnia
sample and N = 4,358 (68%) in the hypersomnia sample. Of
the females, 77.3% of reported insomnia while 22.7% do not;
68.1% of females reported hypersomnia while 31.9% did not. In
males, 79% reported insomnia while 21% did not; 75% reported
hypersomnia while 25% did not.
FIGURE 1 | Bar plot for Insomnia. The x-axis displays eight different p-value
thresholds derived from the fast-score option in PRSice. R2 represents
Nagelkerke’s R-squared and the values on the top of the bars represent the
p-values for that threshold.
TABLE 2 | Insomnia findings.
Threshold R2 P Coefficient Standard error # of SNPs
0.001 2.71E-04 0.277 0.032 0.029 844
0.05 1.75E-03 0.006 0.081 0.029 11,008
0.1 1.17E-03 0.024 0.067 0.029 17,846
0.2 4.41E-04 0.165 0.041 0.029 28,837
0.3 5.55E-04 0.119 0.046 0.029 38,202
0.4 4.56E-04 0.158 0.042 0.029 46,391
0.5 2.27E-04 0.319 0.029 0.029 53,454
1 1.64E-04 0.397 0.025 0.029 75,711
R2 represents Nagelkerke’s R-squared; P represents the p-value; # represents Number.
Insomnia
Prior to applying Bonferroni multiple test corrections (0.05/3),
only two of the p-value thresholds were significant in our model
at a p ≤ 0.05, p = 0.05 and p = 0.1 (Figure 1). The threshold
of p = 0.05 explained <1% of variance in the risk of insomnia
(R2 = 1.75E-03) (Table 2). The p = 0.1 threshold also explained
marginal variance (R2 = 1.17E-03) (Table 2). Only the p-value
threshold of p = 0.05 remained significant after test corrections
were applied.
The sensitivity analysis for a p-value threshold of p = 0.05
revealed that significance increased when QI6C was removed
from the analysis (p= 0.002) (Table 3). The remainder of results
of the leave-one-out analysis can be found in Table 3.
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TABLE 3 | Leave-one-out analysis results.
R2 P Coefficient Standard error Sample size
COF2 1.43E-03 0.0133 0.07354 0.02971 117
GRND 1.79E-03 0.00915 0.08398 0.03222 737
NES1 2.03E-03 0.00853 0.0891 0.03387 1,371
QI3C 1.94E-03 0.00489 0.08532 0.03032 484
QI6C 2.36E-03 0.00209 0.09411 0.03058 579
QIO2 1.47E-03 0.015 0.07426 0.03054 548
RAD3 1.23E-03 0.0455 0.06969 0.03484 1,592
RAGE 1.70E-03 0.00789 0.08021 0.03019 313
RAI2 1.69E-03 0.00664 0.08017 0.02953 21
RAU2 1.77E-03 0.00558 0.08194 0.02957 29
STM2 1.92E-03 0.00604 0.08295 0.03021 907
R2 represents Nagelkerke’s R-squared; P represents the p-value.
Hypersomnia
No significant p-value thresholds were identified when using
summary statistics for “Napping” and “Dozing.” Results for
both can be found in Supplementary Tables 1, 2 as well as
Supplementary Figures 1, 2.
DISCUSSION
Simply, polygenic risk scores are the sum of alleles per locus
weighted by an estimate of the alleles’ effect sizes based on GWAS
summary statistics (38, 39). The most popular method, and
arguably the most straight-forward is the pruning+ thresholding
method, which is available using PRSice (v2) software (37). First,
SNPs are pruned based on linkage disequilibrium so that one is
left with a smaller number of independent SNPs. Second, eight
p-value cut-off scores are used to construct the eight thresholds
(37–39). In order to account for our covariates, and maximize
power, we performed a linear regression on the PRS scores
for each study, standardized the residuals, and then used the
standardized residuals to perform a logistic regression on our
phenotypes of interest, insomnia and hypersomnia.
First, we found that the prevalence rates for insomnia are
representative of the prevalence rates from other reports (8, 40).
The prevalence of hypersomnia in our sample is slightly higher
than others have reported (8, 40). Interestingly, the prevalence
of insomnia between sexes was similar, but the prevalence of
hypersomnia in males was 7% higher than in females. The
direction of our hypersomnia results is in accordance with prior
literature, which suggests depressed males are more likely to
experience hypersomnia than depressed females. However, the
study also suggests a more significant difference than observed in
our results (41). However, their sample was significantly smaller
(N < 500, which may explain the difference in prevalence rates).
In insomnia, we found that PRS scores for SNPs with a p-
value threshold of ≤0.05 in the insomnia GWAS marginally
predicted insomnia in our PGC MDD cohort. However, <1%
of variance was explained by these markers. This truly is
not surprising given that insomnia is already known to be a
polygenic disorder with an estimated SNP-based heritability to
be 7% in the UK Biobank sample whose summary statistics
we used (17). This is much lower than the heritability of
insomnia estimated using twin studies, which suggests 38–
59% (17, 42). The substantial range in heritability was due
to sex differences, as the heritability of insomnia was much
higher in females (59%) than males (38%), which is why we
opted to include sex as a covariate (42). Furthermore, there
are many sleep-related changes that differ between the sexes,
including sex differences in the homeostatic response to sleep
as well as slow wave amplitude during non-rapid-eye movement
sleep (43, 44).
The other point we would like to note about the insomnia
findings comes from our leave-one-out analysis. We noticed that
our results became more significant when QI6C was removed
from the analysis. Both the p-value became more significant (p
= 0.002) and the variance explained increased (R2 = 2.36−03),
which suggests that this dataset is more heterogenous. Indeed,
QI6C is a community sample with diagnoses based on self-report
questionnaires. Interestingly, QIO2 is also a community sample,
recruited in an identical manner to QI6C; but when this sample
is removed, significance is decreased. As with all studies, there
are a few other limitations to this work. First, the phenotype
we are using to characterize insomnia and hypersomnia are
based on self-report data. Some studies suggest that self-reported
sleep measures differ from objectively measured sleep data and
therefore interpretation of data may be more limited (45).
Secondly, there are numerous lifestyle factors known to affect
sleep for which we were unable to covary. For example, we were
unable to include medications in our analyses. Arguably, almost
all of the medications on the market today can affect sleep (46).
One of the most well-known classes to influence sleep is sleep
medications, such as sedative/hypnotics, which are commonly
used to treat insomnia (47). Benzodiazepines are another class
of medication used to induce sleep (47). Interestingly, in 2010,
20.8 million prescriptions for sleep medication were written in
the USA, a 293% increase from the number written in 1999,
which confirms how common these sleep medications are used
(48). There are also substances that promote insomnia (47). For
example, there is extensive evidence that proves that caffeine
reduces sleep quality and duration (49). This would likely bias
one’s subjective opinions of their sleep. Other lifestyle factor
that can negatively affect restorative sleep are regular stress
and a lack of routine exercise (50). Third, the unique aspect
regarding the PGC-MDD sample is that it is comprised of
many smaller samples, including variations such as different
genotyping platforms. This means, to control for potential
sample effects, the sample origin should be included in the
analysis, which negatively affects the power of the analyses. A
recent study has also suggested seven subtypes of insomnia (51).
Although it would have been interesting to investigate these
subtypes in our sample, to determine if one has a stronger
genetic basis than others, we were unable to do so as we were
limited by the phenotype data. In future, we hope to be able to
extend upon our results by incorporating these various subtypes
into a model. Finally, despite the fact that the sample sizes
were similar for both phenotypes of interest (insomnia and
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hypersomnia), we were only able to provide evidence for genetic
overlap with insomnia. We hypothesize our lack of findings
for hypersomnia was because we were using GWAS summary
statistics for napping and dozing to represent hypersomnia.
This does not fully capture hypersomnia, a broad term used
for a variety of sleep disorders ranging from narcolepsy to
idiopathic hypersomnia.
To the best of our knowledge, this study is the first of its
kind to investigate and find genetic overlap between self-reported
insomnia in the general population and depressed individuals.
This could have important implications on treating MDD and
insomnia going forward. Although the results need to be taken
with caution as this is a preliminary study and very little variance
can be accounted for by the genes implicated in insomnia in the
UK Biobank, suggesting that the genetics overlap is minimal.
Further research should focus on a similar study design, but
using objectively measured sleep data, which should provide
more precision for sleep measures. Overall, our results may
make helpful contributions toward more accurate diagnosis and
personalized treatment.
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